| ［1］ |
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis［J］. Nat Rev Dis Primers, 2016,2:16082. doi: 10.1038/nrdp.2016.82.<br />
|
| ［2］ |
Tonel G, Conrad C. Interplay between keratinocytes and immune cells⁃⁃recent insights into psoriasis pathogenesis［J］. Int J Biochem Cell Biol, 2009,41（5）:963⁃968. doi: 10.1016/j.biocel.2008.10.022.<br />
|
| ［3］ |
Zenz R, Eferl R, Kenner L, et al. Psoriasis⁃like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins［J］. Nature, 2005,437（7057）:369⁃375. doi: 10.1038/nature03963.<br />
|
| ［4］ |
Zenz R, Eferl R, Scheinecker C, et al. Activator protein 1 （Fos/Jun） functions in inflammatory bone and skin disease［J］. Arthritis Res Ther, 2008,10（1）:201. doi: 10.1186/ar2338.<br />
|
| ［5］ |
Johansen C, Kragballe K, Rasmussen M, et al. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin［J］. Br J Dermatol, 2004,151（3）:600⁃607. doi: 10.1111/j.1365⁃2133.2004.06088.x.<br />
|
| ［6］ |
Haider AS, Duculan J, Whynot JA, et al. Increased JunB mRNA and protein in psoriasis vulgaris lesions［J］. J Invest Dermatol, 2006,126（4）:912⁃914. doi: 10.1038/sj.jid.5700183.<br />
|
| ［7］ |
Shi ZR, Tan GZ, Cao CX, et al. Decrease of galectin⁃3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis［J］. J Autoimmun, 2018,89:30⁃40. doi: 10.1016/j.jaut.2017.11.002.<br />
|
| ［8］ |
Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratino⁃cytes and immunocytes required for development of psoriasis in a novel transgenic mouse model［J］. Nat Med, 2005,11（1）:43⁃49. doi: 10.1038/nm1162.<br />
|
| ［9］ |
Gao Q, Liang X, Shaikh AS, et al. JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hemato⁃poietic diseases［J］. Curr Drug Targets, 2018,19（5）:487⁃500. doi: 10.2174/1389450117666161207163054.<br />
|
| ［10］ |
Miyoshi K, Takaishi M, Nakajima K, et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA⁃21, a Stat3 inhibitor［J］. J Invest Dermatol, 2011,131（1）:108⁃117. doi: 10.1038/jid.2010.255.<br />
|
| ［11］ |
Nakajima K, Sano S. Mouse models of psoriasis and their relevance［J］. J Dermatol, 2018,45（3）:252⁃263. doi: 10.1111/1346⁃8138. 14112.<br />
|
| ［12］ |
Hirai T, Kanda T, Sato K, et al. Cathepsin K is involved in develop⁃ment of psoriasis⁃like skin lesions through TLR⁃dependent Th17 activation［J］. J Immunol, 2013,190（9）:4805⁃4811. doi: 10.4049/jimmunol.1200901.<br />
|
| ［13］ |
Takaishi M, Nakajima K, Ouyang W, et al. Psoriasis⁃like skin lesions are dependent on IL⁃23 but develop in the absence of IL⁃22 in a model mouse［J］. J Dermatol Sci, 2014,73（3）:261⁃264. doi: 10.1016/j.jdermsci.2013.11.008.<br />
|
| ［14］ |
Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflam⁃mation facilitates the onset of arthritis in a mouse model［J］. J Invest Dermatol, 2015,135（2）:445⁃453. doi: 10.1038/jid.2014.426.<br />
|
| ［15］ |
Pasparakis M, Courtois G, Hafner M, et al. TNF⁃mediated inflamma⁃tory skin disease in mice with epidermis⁃specific deletion of IKK2［J］. Nature, 2002,417（6891）:861⁃866. doi: 10.1038/nature00820.<br />
|
| ［16］ |
Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte⁃induced psoriasis⁃like skin inflammation［J］. J Clin Invest, 2006,116（8）:2094⁃2104. doi: 10.1172/JCI27179.<br />
|
| ［17］ |
Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis［J］. Blood, 2003, 102（1）:161⁃168.<br />
|
| ［18］ |
Voskas D, Jones N, Van Slyke P, et al. A cyclosporine⁃sensitive psoriasis⁃like disease produced in Tie2 transgenic mice［J］. Am J Pathol, 2005,166（3）:843⁃855. doi: 10.1016/S0002⁃9440（10）62305⁃X.<br />
|
| ［19］ |
Danilenko DM. Review paper: preclinical models of psoriasis［J］. Vet Pathol, 2008,45（4）:563⁃575. doi: 10.1354/vp.45⁃4⁃563.<br />
|
| ［20］ |
Swindell WR, Johnston A, Carbajal S, et al. Genome⁃wide profiling of five mouse models identifies similarities and differences with human psoriasis［J］. PLoS One, 2011,6（4）:e18266. doi: 10.1371/journal.pone.0018266.<br />
|
| ［21］ |
Bocheńska K, Smolińska E, Moskot M, et al. Models in the research process of psoriasis［J］. Int J Mol Sci, 2017,18（12）:2514. doi: 10.3390/ijms18122514.<br />
|
| ［22］ |
Schön MP. Animal models of psoriasis: a critical appraisal［J］. Exp Dermatol, 2008,17（8）:703⁃712. doi: 10.1111/j.1600⁃0625. 2008.00751.x.<br />
|
| ［23］ |
Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte over of IL⁃17C promotes psoriasiform skin inflammation［J］. J Immunol, 2013,190（5）:2252⁃2262. doi: 10.4049/jimmunol.1201505.<br />
|
| ［24］ |
Shepherd J, Little MC, Nicklin MJ. Psoriasis⁃like cutaneous inflammation in mice lacking interleukin⁃1 receptor antagonist［J］. J Invest Dermatol, 2004,122（3）:665⁃669. doi: 10.1111/j.0022⁃ 202X.2004.22305.x.<br />
|
